Ascendis agrees to pay BioMarin 20% of U.S. YUVIWEL net sales
Ascendis Pharma (ASND) has agreed to pay BioMarin 20% of U.S. net sales and 18% in the EU, South Korea, and Brazil for YUVIWEL (navepegritide) through 2030. The deal resolves all litigation and grants Ascendis a non-exclusive, worldwide license. Ascendis expects over €500M in operating cash flow by 2026 and €5B in revenue by 2030, with FDA approval for YUVIWEL anticipated in February 2026.
How this was made
The 30-second read
Why it matters
The settlement removes legal uncertainty for Ascendis while providing BioMarin a new revenue stream, but introduces a significant royalty cost for Ascendis that may affect profitability.
Market read
The deal is material for both companies' earnings outlooks and may influence biotech sector sentiment on licensing structures.
What to watch
Future regulatory approvals in the EU, South Korea, and Brazil will determine the actual royalty revenue timeline.
Background
Ascendis Pharma and BioMarin resolved ongoing litigation and established a royalty‑bearing license for the navepegritide product YUVIWEL, with detailed royalty rates and cash‑flow expectations.
Ticker impact
Ascendis Pharma entered a binding term sheet with BioMarin for a global settlement and royalty-bearing license on its navepegritide product YUVIWEL.
Short-term price pressure from margin concerns, but long-term upside if settlement clears path for commercial rollout.
Royalty burden is material; litigation risk removal is positive. Market will weigh margin impact versus risk mitigation.
BioMarin granted Ascendis a non‑exclusive worldwide license to navepegritide and will receive royalties on its sales.
Potential modest share‑price lift from added royalty income expectations.
Royalty income is incremental and dependent on Ascendis commercial success; market may view it favorably.
Market effects
The biotech sector may see increased focus on royalty‑based licensing deals as a risk‑mitigation tool.
U.S. and EU markets could react to the royalty terms affecting profit expectations for both companies.
The agreement highlights cross‑border collaboration in rare‑disease therapeutics, relevant to global biotech investors.
Counterpoint
The 20% royalty could severely erode Ascendis margins, outweighing the benefit of litigation resolution.
Key entities
- CompanyAscendis Pharma
US‑listed biotech (NASDAQ: ASND) developing navepegritide for achondroplasia.
- CompanyBioMarin Pharmaceutical
US‑listed biotech (NASDAQ: BMRN) licensing its technology and receiving royalties.
